Cofepris approves a new flu vaccine

Federal Committee on Health Risk Protection (Coffey Ply) to declare approval new flu vaccine For those 65 and over.

in its fortnightly report on treatment expansion Biological Quadrivalent Against Influenza A and B Subtypes (inactivated split virus).

This flu shot for seniors is made by the company Sanofi-Aventis Mexico In the name of Fluzone High Dose Quadrivalent.

biological Prevent Disease and Complications related to hospitalized with pneumonia Seniors over the age of 65.

As background, the 2021 Cofepris Committee on New Molecules (CMN) and Subcommittee on Evaluation of Biotechnology Products (SEPB) submitted this influenza vaccine for analysis.The experts unanimously released in favorBased on the evidence presented.

CMN and SEPB do not have the authority to authorize products, but the technical opinions they issue, whether favorable or not, are included in the company’s filings with the Health Licensing Board.

When the product is qualified and the manufacturer does not need to make changes, it can apply for hygiene registration. The flu vaccine was approved two years after it was approved.

flu is a acute viral respiratory disease This is more common in winter, which is why annual vaccinations are recommended, especially for vulnerable groups such as the elderly and those with risk factors.

Symptoms of the illness include fever over 38 degrees, runny and red nose, chills, headache, muscle pain, weakness, chest pain, diarrhea and mild sore throat.

One of the most common complications of influenza is pneumonia. In severe cases, this health problem caused by the virus can lead to hospitalization and, if left unchecked, even death.

In July, the Undersecretary for Prevention and Health Promotion, Hugo López-Gatel, announced that the 2023 Influenza Vaccination Day will be held in conjunction with the application of the Covid-19 vaccine. So far, no biologics have been announced to immunize people susceptible to these diseases.

The flu vaccine isn’t the only drug recently approved in Mexico, with 14 drugs, 145 medical devices and seven clinical trials for neurological, psychiatric and oncological conditions, Cofepris noted in its latest report.

The committee emphasized the importance of antiplatelet agent As well as tools such as intravascular ultrasound catheters, intervertebral fixation devices, and intracranial self-expanding stents.

In clinical trials, Cofepris specifically mentions one for the treatment of systemic lupus erythematosus another related chronic kidney transplant rejection.

Regarding medicines, here is a list of newly approved medicines, according to their scope of application:

– Cardiology: Cangrelo (Ken Grexall)

– Steroids: Hydrocortisone (Intiaro) and prednisolone (Quimunex)

– Hematology: rivaroxaban (Harvey).

– Infectious diseases: clarithromycin (Clarix).

– Neurology: Dimethyl fumarate (Drasco) and levetiracetam (Ben Leaf).

– Ophthalmology: Travoprost (Mexican).

– Oncology: palbociclib (Intiaro), cabazitaxel and gefitinib (Tinalib).

– Psychiatry: zolpidem (child).

Cofepris regularly publishes Therapeutic Expansion Reports, which announce approved new drugs, devices and trials, as “part of the agency’s practice of transparency with regulated industry and patients, a core goal of agility, fairness and transparency.”